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Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer, and its mo-
lecular pathogenesis still remains to be elucidated. This study aimed to evaluate the preva-
lence and implication of anaplastic lymphoma kinase (ALK) copy number change in
IBC patients.
Methods
We retrospectively collected formalin-fixed, paraffin-embedded tumor tissues and medical
records of IBC patients from several institutes in Korea. ALK gene copy number change
and rearrangement were assessed by fluorescence in situ hybridization (FISH) assay, and
ALK expression status was evaluated by immunohistochemical (IHC) staining.
Results
Thirty-six IBC patients including those with HER2 (+) breast cancer (16/36, 44.4%) and
triple-negative breast cancer (13/36, 36.1%) were enrolled in this study. ALK copy number
gain (CNG) was observed in 47.2% (17/36) of patients, including one patient who harbored
ALK gene amplification. ALK CNG (+) patients showed significantly worse overall survival
compared to ALK CNG (-) patients in univariate analysis (24.9 months vs. 38.1 months,
p = 0.033). Recurrence free survival (RFS) after curative mastectomy was also significantly
shorter in ALK CNG (+) patients than in ALK CNG (-) patients (n = 22, 12.7 months vs. 43.3
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months, p = 0.016). Multivariate Cox regression analysis with adjustment for HER2 and
ER statuses showed significantly poorer RFS for ALK CNG (+) patients (HR 5.63, 95%
CI 1.11–28.44, p = 0.037).
Conclusion
This study shows a significant presence of ALK CNG in IBC patients, and ALK CNGwas as-
sociated with significantly poorer RFS.
Introduction
Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer, characterized
by erythematous and edematous changes of the involved breast with numerous dermal tumor
emboli and lymphatic dilatation upon microscopic examination. IBC comprises 1%–6% of all
breast cancers, and the distinct clinicopathological features and dismal prognosis distinguish
IBC from locally advanced non-IBC. The 5-year survival rate of IBC patients is about 40% de-
spite recent advances in multimodal treatment including chemotherapy, surgery, and radio-
therapy [1,2], and the median recurrence free survival (RFS) and the median overall survival
(OS) of IBC are 2.3 years and 4.2 years, respectively, according to a previous report [3]. Consid-
ering that IBC is almost always found to be an advanced disease, effective systemic therapy is
imperative. However, a specific targeted therapy that could improve treatment outcome of IBC
patients is yet to be developed. The majority of IBCs are hormone receptor-negative, and the
proportion of HER2-positive and triple-negative breast cancer (TNBC) cases is higher in IBC
than in non-IBC. Although several genes such as RHO-C GTPase, p53, and WISP3 have been
shown to be altered in IBC tumors [4–7], the molecular pathogenesis and target identification
of IBC still needs to be elucidated [8].
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that has been regarded as a
valuable molecular target following the success of a cMet and ALK inhibitor, crizotinib, in
non-small cell lung cancer (NSCLC) tumors with ALK gene rearrangement [9,10]. ALK rear-
rangement and mutation are involved in the pathogenesis of human malignancies such as ana-
plastic lymphoma, neuroblastoma, and myofibroblastic tumor. In addition to ALK gene
rearrangement, ALK gene copy number gain (CNG) and amplification have also been reported
in NSCLC [11], colorectal carcinoma [12], renal cell carcinoma (RCC) [13], rhabdomyosarco-
ma [14], and neuroblastoma tumor [15], but their biological significance and relation to ALK
inhibitor susceptibility remain uncertain.
Recent studies have reported that there are considerable CNGs and amplifications in IBC
cell lines and IBC patient tumors [16–18]. Furthermore, a preclinical study showed that ALK-
amplified tumor cells isolated from IBC patients were highly sensitive to the anti-proliferative
effect of crizotinib, but resistant to paclitaxel [16]. Based on these reports, ALK CNG and am-
plification are potentially druggable genetic alterations in IBCs, and validation of their clinical
implications and prognostic relevance is warranted. This study aimed to evaluate the preva-
lence and implication of ALK copy number changes in IBC patients. We used formalin-fixed
paraffin-embedded (FFPE) tumors to investigate protein expression levels of ALK using immu-
nohistochemistry (IHC), to evaluate the frequency of ALK gene amplifications and copy num-
ber changes with fluorescence in situ hybridization (FISH), and to elucidate the prevalence,
clinicopathological characteristics, and prognostic relevance of ALK gene alterations in IBC.
ALK Gene Copy Number Change in Inflammatory Breast Cancer
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Materials and Methods
Ethics statement
This study was approved by the Institutional Review Board (IRB) of each involved institution:
Severance Hospital, Asan Medical Center, National Cancer Center, and Gangnam Severance
Hospital. Written informed consents were obtained from all patients for genetic analysis of
tumor tissues.
Patients
Tumor tissues and medical records of IBC patients were retrospectively collected from several
institutes in Korea (Severance Hospital, Asan Medical Center, National Cancer Center, and
Gangnam Severance Hospital). Patients were diagnosed with invasive ductal or lobular carci-
noma of the breast between August 1996 and December 2011, and fulfilled the diagnostic crite-
ria of IBC: diffuse erythema and dermal edema (peau d’orange) of a third or more of the skin of
the breast, based on the definition of IBC by the American Joint Committee on Cancer
(AJCC). Medical records were reviewed in regards to clinical parameters including patient age
at initial diagnosis, pathologic tumor stage based on the seventh edition of the AJCC, date of di-
agnosis, date of recurrence, date of death, treatment modalities that each patient received (sur-
gery type, chemotherapy regimen, radiation therapy, and hormone therapy), and pathologic
reports including estrogen receptor (ER), progesterone receptor (PR), and HER2 status. All pa-
tients were followed up at each institute until the date of death or the last day of follow up, and
the median follow up was 26.2 months (95% confidence interval [CI], 11.8–40.6 months).
ALK Fluorescence in situ hybridization (FISH)
We performed FISH analysis in Samkwang Medical Laboratory, which has certification from
CAP (College of American Pathologists). To assess the genetic status of ALK, we used an ALK
LSI break-apart (2p23) probe (Abbott Molecular Inc., Des Plaines, IL) to detect rearrangements
involving the ALK gene and to determine copy numbers. Briefly, representative 4 μm sections
of blocks were mounted on slides, air-dried, and baked for 2 hours at 60°C in ThermoBrite.
The slides were deparaffinized, dehydrated, immersed in 0.2N HCl, and incubated in 1M
NaSCN for 35 minutes at 80°C. Sections were then immersed in protease solution, and the tis-
sues were fixed in 10% neutral-buffered formalin. The slides were incubated in a humidified at-
mosphere (Hybrite, Vysis) at 73°C for 3 minutes and at 37°C for 19 hours followed by
immersion in 0.4 x SSC/0.3% NP-40 at room temperature and at 73°C for 2 minutes. The
probe was applied, and the sections were appropriately covered and sealed. After washing and
drying, nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI). FISH signals
were assessed under a Nikon ECLIPSE 80i (Nikon, Japan) equipped with a triple-pass filter
(DAPI/Green/Orange; Nikon, Japan). Non-rearranged ALK presented as an overlapping or-
ange/red and green (yellowish) signals. The probes were considered typically rearranged when
separated by green and orange/red signals (by at least three times the signal diameter) and
were atypically rearranged when a single orange or green signal was observed. We considered
the ALK rearrangement to be present if 15% of nuclei had rearranged FISH signal patterns. For
ALK copy number status determination, we reviewed previous studies in various tumors
[11,13,14,19], and predefined the criteria for ALK gene copy number status prior to the FISH
experiment. We arbitrarily classified ALK gene copy number status according to the frequency
of tumor cells with specific numbers of copies: trisomy, as 3 fusion signals in30% of cells and
4 fusion signals in<10% of cells; polysomy, as4 fusion signals in10% of analyzed cells;
and amplification, as6 fusion signals in10% of analyzed cells. An ALK gene copy number
ALK Gene Copy Number Change in Inflammatory Breast Cancer
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below the above criteria thresholds was defined as disomy (Fig. 1). We classified disomy as
ALK CNG (-), and trisomy, polysomy, and amplification as ALK CNG (+). The FISH results
were interpreted by three independent evaluators (Wooyoung Jung, Yoonjung Kwon, and
Yoonmi Seok) who were blinded for clinical data, and any discordance among evaluators was
discussed until a consensus was reached.
Immunohistochemical (IHC) assay
We retrieved FFPE tissue specimens of 27 patients for ALK IHC. All archival hematoxylin and
eosin (H&E)-stained slides for each patient were reviewed by one pathologist. ALK IHC was
performed on 4-μm-thick FFPE tissue specimens using mouse monoclonal antibody for ALK
(Invitrogen, 1:200, polyclonal, Fig. 2). ALK staining was scored according to the proportion of
stained cells to total analyzed cells. The immunohistochemistry of ER, PR, and HER2 and
FISH for HER2 were also conducted by each of the four institutes according to the recom-
mended guidelines of the American Society of Clinical Oncology and College of American Pa-
thologists [20,21].
Statistical analysis
Data were processed using SPSS for Windows, version 20.0 (SPSS Inc., Chicago, IL, USA).
Clinicopathologic characteristics and expression status of ER, PR, and HER2 were compared
Fig 1. Representative ALK fluorescent in situ hybridization (FISH) images in IBC patients. (A) disomy, (B) ALK copy number gain (trisomy), (C) ALK
copy number gain (polysomy), and (D) ALK amplification.
doi:10.1371/journal.pone.0120320.g001
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according to ALK status using either a chi-square test or Fisher’s exact test. Comparisons of the
ALK IHC scores with mean ALK copy numbers were performed using Spearman’s rank corre-
lation test. RFS and OS were calculated from the time of initial treatment to the time of event
of interest, recurrence after surgery, death, or final clinical follow up. Patient survival was esti-
mated by the Kaplan-Meier method and compared with a log-rank test. Multivariate analysis
was performed using a Cox-proportional hazard model to estimate survival with adjustment
for factors including AJCC stage, HER2 status, and ER status. Statistical significance was as-
sumed when the p value was less than 0.05; all tests were two-sided.
Results
Patient characteristics
Thirty-six IBC patients from four institutes showing HER2-positive disease (44.4%) and TNBC
(36.1%) in frequent order were studied. The median age of patients was 51 (range, 29.7–65.2
years), and the median OS was 37.2 months (95% CI, 17.4–57.0 months). Most of the patients
had a high clinical node stage (77.8% of patients were higher than N1). Distant metastasis was
present at the time of diagnosis in 33.3% of patients (12/36), although no patients had initial
brain metastasis. Most stage III patients (n = 22, 91.7%) underwent modified radical mastecto-
my, and 6 out of 12 stage IV patients also underwent palliative mastectomy after systemic che-
motherapy. Among 28 patients who underwent mastectomy, 23 received neoadjuvant
chemotherapy before surgery, and 5 patients received adjuvant chemotherapy after surgery. In
Fig 2. Representative immunohistochemical staining of ALK. (A) negative staining, (B)10% staining, (C) 50% staining, and (D) 80% staining of
tumor cells.
doi:10.1371/journal.pone.0120320.g002
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total, 35 out of 36 (97.2%) patients received chemotherapy, including 7 patients who received
palliative chemotherapies without surgery (Table 1). A summary of chemotherapy agents that
patients received can be found in S1 Table.
ALK CNG and its correlation with clinicopathological characteristics
ALK CNG (trisomy, polysomy, and amplification) was observed in 17 out of 36 (47.2%) IBC
patients; among them, one patient harbored ALK gene amplification. None of the patients had
ALK rearrangement in this study. The clinical characteristics of the patients were similar for
both the ALK CNG (-) group and the ALK CNG (+) group (Table 1), and received chemother-
apy agents were not different between the two groups (S2 Table). There was no significant dif-
ference in ER/PR/HER2 status according to ALK CNG, although the proportion of TNBC was
higher in ALK CNG (+) patients, without statistical significance (41.2% vs. 26.3%, p = 0.345).
The other tumor subtypes were not relevant to ALK CNG status in this study. All of the new
brain metastasis during the follow up period occurred in ALK CNG (+) patients (4/17, 23.5%),
and none occurred in ALK CNG (-) patients.
Immunohistochemical (IHC) of ALK
We performed IHC staining of ALK to correlate gene copy number status and ALK protein ex-
pression in 27 patients (Table 2). ALK expression was found in 6 out of 13 ALK CNG (+) IBC
tumors, and 9 out of 14 ALK CNG (-) patient tumors. There was no significant correlation be-
tween mean ALK gene copy number and ALK IHC score (p = 0.767).
ALK CNG status and patient survival
In univariate analysis, median OS was significantly worse in ALK CNG (+) than in ALK CNG
(-) (24.9 months vs. 38.1 months, p = 0.033, Fig. 3). For stage III patients who underwent modi-
fied radical mastectomy (n = 22), RFS was also significantly shorter in ALK CNG (+) patients
than in ALK CNG (-) patients. (12.7 months vs. 43.3 months, p = 0.016). We also performed
subgroup OS analysis for both stage III (n = 24) and stage IV (n = 12) subgroups. There was a
tendency of shorter OS in ALK CNG (+) patients compared to ALK CNG (-) patients in the
stage III subgroup (26.3 months vs. 60.6 months, p = 0.058, S1 Fig.), however, it was not statis-
tically significant. There was no OS difference between ALK CNG (+) and ALK CNG (-) pa-
tients in the stage IV subgroup (p = 0.574). Comparison of progression-free survival was not
performed for metastatic IBC due to the small sample size (n = 12). Multivariate analysis of OS
and RFS using the Cox-proportional hazard model was performed with adjustment for several
factors (AJCC stage, ER status, and HER2 status for OS; ER status and HER2 status for RFS).
Multivariate analysis showed significantly worse RFS for ALK CNG (+) patients than for ANK
CNG (-) patients (HR 5.63, 95% CI 1.11–28.44, p = 0.037). There was also a tendency of worse
OS in ALK CNG (+) patients in multivariate analysis (HR 2.63, 95% CI 0.86–8.11, p = 0.076,
Table 3).
Discussion
Therapeutic targeting of ALK rearrangement has led to a remarkable improvement of survival
in ALK-rearranged NSCLC patients [10,22], and many studies are underway to reveal the on-
cogenic role of ALK in other tumor species. Beyond ALK gene rearrangement, ALK gene aber-
rations such as mutations, copy number changes, and amplifications have also been reported
in various malignancies, and their clinical implication and susceptibility to ALK inhibitors are
attracting interest amongst researchers. ALK gene fusion occurs in limited subsets of cancer
ALK Gene Copy Number Change in Inflammatory Breast Cancer
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Table 1. ALK Copy Number Gain and Baseline Clinicopathological Characteristics.
Characteristic Total (N = 36) ALK CNG (-) (N = 19) ALK CNG (+) (N = 17) p-valuea
Age, years
Median (range) 51 (29.7~65.2 yrs) 48 (32~64yrs) 51 (28.0~72.0 yrs) 0.744
Clinical tumor stage
T4d 36 (100%) 19 (100%) 17 (100%)
Clinical node stage
N0 1 (2.8%) 1 (5.3%) 0 (0%) 0.498
N1 7 (19.4%) 4 (21.1%) 3 (17.6%)
N2 8 (22.2%) 4 (21.1%) 4 (23.5%)
N3 20 (55.6%) 10 (52.6%) 10 (58.8%)
AJCC stage
stage III 24 (66.7%) 13 (68.4%) 11 (64.7%) 0.813
stage IV 12 (33.3%) 6 (31.6%) 6 (35.3%)
Operation
No 8 (22.2%) 5 (26.3%) 3 (17.6%) 0.695
Yes 28 (77.8%) 14 (73.7%) 14 (82.4%)
Primary chemotherapy
Neoadjuvant 23 (63.9%) 11 (57.9%) 12 (70.6%) 1
Adjuvant 5 (13.9%) 3 (15.8%) 2 (11.8%)
Palliative 7 (19.4%) 4 (21.1%) 3 (17.6%)
None 1 (2.8%) 1 (5.3%) 0 (0.0%)
Use of hormone therapy
No 26 (72.2%) 13 (68.4%) 13 (76.5%) 0.717
Yes 10 (27.8%) 6 (31.6%) 4 (23.5%)
Use of Radiation therapy
No 17 (47.2%) 11 (57.9%) 6 (35.3%) 0.175
Yes 19 (52.8%) 8 (42.1%) 11 (64.7%)
ERb
Negative 25 (69.4%) 12 (63.2%) 13 (76.5%) 0.387
Positive 11 (30.6%) 7 (36.8%) 4 (23.5%)
PRb
Negative 28 (77.8%) 14 (73.7%) 14 (82.4%) 0.532
Positive 8 (22.2%) 5 (26.3%) 3 (17.6%)
HER2
Negative 20 (55.6%) 10 (52.6%) 10 (58.8%) 0.709
Positive 16 (44.4%) 9 (47.4%) 7 (41.2%)
Subtype
ER(+)/HER2(-) 7 (19.4%) 5 (26.3%) 2 (11.8%) 0.468
ER(+)/HER2(+) 6 (16.7%) 4 (21.1%) 2 (11.8%)
ER(-)/HER2(+) 10 (27.8%) 5 (26.3%) 5 (29.4%)
TNBC 13 (36.1%) 5 (26.3%) 8 (47.1%)
ALK, anaplastic lymphoma kinase; CNG, copy number gain; AJCC, American Joint Committee on Cancer; ER, estrogen receptor; PR, progesterone
receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.
a p value was calculated either by chi-square test or Fisher’s exact test.
bAll PR positive patients were also ER positive.
doi:10.1371/journal.pone.0120320.t001
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such as NSCLC, anaplastic large cell lymphoma, and inflammatory myofibroblastic tumor,
whereas ALK mutation and copy number gain were observed in a wide range of cancers.
We evaluated the prevalence of ALK gene expression and copy number change, as well as
their relationships to clinical characteristics and prognosis in IBC patients. We found frequent
copy number gains of the ALK gene (47.2%) in FISH analysis, and there was also a presence of
ALK protein expressions (55.5%) in IBC tumors, found in IHC analysis. However, ALK CNG
was not correlated with ALK protein expression level in this study. ALK CNG positivity was in-
dependently associated with significantly poorer RFS in survival analysis. Based on our finding,
we suggest that ALK CNGmay play a role in IBC pathogenesis and contribute to poor progno-
sis of IBC patients. Since many IBC patients receive standard chemotherapy that is similar to
non-IBC patients without specific molecular targets, the validation of the relationship between
ALK CNG and susceptibility to ALK inhibitor calls for further investigation.
Previous studies did not observe ALK rearrangement in breast cancer patients [23,24].
However, Perez-Pinera et al. demonstrated the expression of ALK in different histological
Table 2. Comparison of ALK Immunohistochemical staining and fluorescence in situ hybridization analysis results. (n = 27).
Number Age AJCC Stage ALKa2F ALKa 3~4F ALKa5F CNG ALK IHC Scoreb Subtype Survival
1 F/45 III 100% 0% 0% Negative 0% TNBC alive
2 F/41 III 100% 0% 0% Negative 40% TNBC death
3 F/64 III 100% 0% 0% Negative 80% ER(-)/HER2(+) death
4 F/64 IV 98% 2% 0% Negative 10% ER(+)/HER2(-) alive
5 F/72 III 97% 3% 0% Negative 0% ER(-)/HER2(+) alive
6 F/37 IV 97% 3% 0% Negative 10% ER(-)/HER2(+) alive
7 F/52 III 95% 5% 0% Negative 50% ER(+)/HER2(+) death
8 F/53 III 94% 5% 1% Negative 10% TNBC death
9 F/44 IV 94% 6% 0% Negative 10% TNBC death
10 F/45 III 91% 9% 0% Negative 0% ER(+)/HER2(+) alive
11 F/47 III 85% 14% 1% Negative 0% ER(-)/HER2(+) alive
12 F/45 III 83% 17% 0% Negative 10% TNBC alive
13 F/63 IV 83% 17% 0% Negative 30% ER(+)/HER2(-) death
14 F/59 III 75% 25% 0% Negative 0% ER(+)/HER2(-) alive
15 F/63 III 70% 30% 0% Positive 20% TNBC death
16 F/51 IV 69% 31% 0% Positive 0% ER(-)/HER2(+) alive
17 F/64 IV 64% 28% 8% Positive 0% TNBC death
18 F/52 III 60% 40% 0% Positive 60% ER(-)/HER2(+) death
19 F/63 III 57% 41% 2% Positive 0% ER(+)/HER2(+) alive
20 F/51 IV 53% 47% 0% Positive 0% TNBC death
21 F/34 III 53% 47% 0% Positive 10% TNBC death
22 F/55 III 45% 55% 0% Positive 0% ER(+)/HER2(+) death
23 F/56 IV 44% 49% 7% Positive 0% ER(-)/HER2(+) death
24 F/59 III 38% 18% 44% Ampliﬁcation 10% ER(+)/HER2(-) death
25 F/28 III 33% 57% 10% Positive 80% TNBC death
26 F/43 III 23% 50% 27% Positive 80% TNBC death
27 F/54 IV 11% 70% 19% Positive 0% TNBC death
AJCC, American Joint Committee on Cancer; ALK, anaplastic lymphoma kinase; CNG, copy number gain; IHC, immunohistochemical staining; ER,
estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.
aALK gene copy number status according to the frequency of tumor cells with speciﬁc numbers of copies in ﬂuorescence in situ hybridization.
bALK IHC score according to the proportion of stained cells to total analyzed cells
doi:10.1371/journal.pone.0120320.t002
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subtypes of human breast cancer [25], and TCGA (The Cancer Genome Atlas Network) geno-
mic analysis showed ALK gene copy number gains in 43 out of 476 breast cancer patients [26].
Importantly, recent studies have reported frequent ALK CNGs in IBC tumors, with a frequency
of 64%–80%, and a preclinical study also found ALK CNG in IBC cell lines and induction of
apoptosis and cell death by crizotinib treatment [16,18]. Although such studies only tested lim-
ited sample size without direct comparison between IBC tumors and non-IBC tumors [16, 18],
Fig 3. Comparison of overall survival and recurrence free survival after mastectomy in ALK CNG (-) patients and ALK CNG (+) patients. (A) overall
survival and (B) recurrence free survival. ALK, anaplastic lymphoma kinase; CNG, copy number gain.
doi:10.1371/journal.pone.0120320.g003
Table 3. Analyses of Prognostic Factors for Overall Survival and Recurrence-free Survival. (Cox-Proportional Harzard Model).
Overall Survival (n = 36) Recurrence-Free Survival (n = 22)
Factors Hazard ratio (95% CI) P- valuea Hazard ratio (95% CI) P- value*
ALK CNG (+) vs. CNG(-) 2.63 (0.86–8.11) 0.076 5.63 (1.11–28.44) 0.037
ER positive vs. negative 0.67 (0.21–2.16) 0.504 0.78 (0.23–2.65) 0.694
HER2 positive vs. negative 0.63 (0.21–1.89) 0.404 0.77 (0.23–2.51) 0.660
AJCC stage IV vs. III 2.74 (0.86–8.73) 0.671
ALK, anaplastic lymphoma kinase; CNG, copy number gain; AJCC, American Joint Committee on Cancer; ER, estrogen receptor; HER2, human
epidermal growth factor receptor 2.
a p values were calculated using the Cox-proportional hazard model.
doi:10.1371/journal.pone.0120320.t003
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ALK has been suggested as a potential druggable target in IBC patients, and its clinical implica-
tion and prognostic significance needs to be elucidated.
Interestingly, recent studies also reported discordance between ALK CNG (or amplification)
on FISH and ALK protein expression on IHC in various tumor tissues [12,18,27–29], and ALK
IHC results were similarly not correlated with ALK CNG in the present study. Although we
did not study the mechanism further, epigenetic regulations and post-transcriptional silencing
may be possible explanations for discordance between ALK CNG and ALK IHC. In addition,
we cannot rule out the possibility that the ALK antibody that we used in the current study was
not sensitive enough to detect ALK protein level change accompanied by ALK CNG. Although
ALK copy number status is not well correlated with ALK IHC, ALK CNG has been associated
with poor prognosis in several malignancies [12,14,30]. Robertson et al. also showed activation
of ALK and its downstream signaling pathways in ALK-amplified IBC cells, as well as in vivo
functional relevance of ALK amplification in an IBC xenograft model [16]. Further functional
studies are required that investigate the molecular mechanisms of ALK CNG upon cancer
pathogenesis and the relationship between ALK CNG and ALK protein expression level.
In this study, we used the FDA-approved FISH probe to evaluate ALK gene status in tu-
mors. In previous studies, the cutoffs of ALK gene copy number gain in FISH have been de-
fined differently in various malignancies [11–14,16,19]. Considering that low-level CNG may
simply reflect DNA duplication of dividing tumor cells, we predefined the cutoff of tumor cell
percentage for trisomy as30%, and polysomy was defined as4 fusion signals in10% to
avoid overestimation of CNG. However, the criteria for ALK CNG determination need to be
refined by further studies.
In this study, the proportion of TNBC was higher in ALK CNG (+) patients (47.1%) than in
ALK CNG (-) (26.3%). Although statistical significance was not reached probably due to the
small sample size, this result suggests that ALK CNG is common in TNBC among four sub-
types of breast cancer. Lehmann et al. have also presented enriched genetic aberrations in ALK
pathways in mesenchymal-type TNBCs [31]. As TNBCs have the worst prognosis and do not
yet have known molecular targets, ALK could provide a potential druggable target especially
for triple-negative IBC.
There are limited numbers of studies on ALK CNG and survival outcome, and not much
has been studied on the relationship between ALK CNG and tumor behavior as yet. However,
ALK CNG has been related to a higher rate of metastatic disease and poor survival in rhabdo-
myosarcoma and colorectal carcinomas [12,14]. Additionally, Kim et al. reported higher ALK
CNG and protein expression in metastatic lesions compared to primary tumors in NSCLC pa-
tients [32]. Our study demonstrated significantly worse RFS for ALK CNG (+) IBC patients
than for ALK CNG (-) patients, and we suggest that ALK CNGmay play a role in IBC progres-
sion and metastasis based on these findings. However, OS was not significantly different ac-
cording to ALK CNG status with our limited sample size and follow up duration, although
there was a tendency of worse OS in ALK CNG (+) patients in multivariate analysis. It is im-
perative to study the prognostic significance of ALK CNG further in other populations with a
larger sample size and longer follow up period.
Although it seems evident that copy number changes of the ALK gene are prevalent in IBC,
the association between high copy number status of ALK and favorable response to ALK inhib-
itors remains undetermined. Several reports have shown effective growth inhibition by crizoti-
nib in neuroblastoma, NSCLC, and IBC cell lines harboring ALK copy number gain or
amplification in preclinical studies [16,33,34]. These findings support the possible therapeutic
potency of ALK inhibitors in the treatment of tumors containing ALK gene copy number gain.
Selective ALK inhibitors are currently under clinical trial in patients with advanced human
solid tumors containing ALK gene alterations. The clinical efficacy of these inhibitors in ALK
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high copied or amplified IBC patients is yet to be known. Results from early phase clinical trials
will help future studies to focus on the oncogenic role of ALK in IBC pathogenesis and the po-
tential effect of ALK inhibitors in IBCs.
There are several caveats to this study. First, we evaluated only Korean IBC patients. Second,
the follow up duration of this study was relatively short, and may have limited sufficient com-
parison of OS between ALK CNG (+) and ALK CNG (-) groups. Third, all data and specimens
were achieved retrospectively, and we used only a single technique to measure ALK CNG. Fi-
nally, the FISH results were interpreted in a single laboratory, although three independent eval-
uators participated. Therefore, a larger study in an independent population of a different
ethnic background with comprehensive analysis of ALK copy number status is warranted.
However, we believe that this is the first study to observe the clinical significance of ALK gene
alterations in IBC.
In summary, this study showed significantly frequent ALK CNG in IBC patients, and ALK
CNG was associated with poorer RFS in curatively resected patients. Our finding suggests that
ALK CNG may have prognostic significance in IBC patients, and it is necessary to explore its
susceptibility to ALK inhibitors.
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